MapLight Therapeutics, Inc. (MPLT) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Sep 18Sep 23Sep 28Oct 1Oct 6Oct 9Oct 14Oct 19

Key dataOct 19, 2026

Open$7.73

From 52W high−79.90%

Volume278640.00

Market cap$444.61M

P/E (TTM)—

P/S (TTM)—

Div yield—

Key dataOct 19, 2026

Open

$7.73

From 52W high

−79.90%

Volume

278640.00

Market cap

$444.61M

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.6x

P/E (TTM)

—

RSI (14)

27.4

MomentumView details →

1D Return

+3.90%

YTD Return

−54.61%

ValuationView details →

P/E (Fwd)

—

P/E (TTM)

—

EV/EBITDA

−0.6x

EV/Sales

—

P/S (TTM)

—

P/B (TTM)

1.3x

ProfitabilityView details →

Gross Margin

—

Net Margin

—

EBITDA Margin

—

ROE (TTM)

−65.99%

ROA (TTM)

−62.39%

Asset Turnover

0.00x

GrowthView details →

Revenue YoY

—

EPS YoY

—

FCF YoY

−72.69%

Revenue CAGR 3Y

—

EPS CAGR 3Y

−95.72%

EBITDA YoY

—

MomentumView details →

1D Return

+3.90%

YTD Return

−54.61%

1Y Return

−56.52%

RSI (14)

27.4

vs 50D SMA

−28.32%

vs 200D SMA

−61.93%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

16.52x

Quick Ratio

16.52x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

EarningsView details →

EPS (Actual)

−$1.32

EPS Surprise

2.15%

Beats (12Q)

1/12

Next Q EPS Est

−$1.18

Avg Surprise (4Q)

−563.88%

Rev Surprise

—

Financials snapshotView financials →

Revenue (TTM)

0.00

Net Income (TTM)

−229.83M

Op. CF (TTM)

−174.67M

Next earningsDec 3, 2026 →

Latest newsMore news →

MapLight Therapeutics reported financial results for the second quarter ended June 30, 2026, ending the quarter with $351.3 million in cash, cash equivalents and investments.67d ago

MapLight Therapeutics reported Phase 2 IRIS results for ML-004 in autism spectrum disorder, with clinically meaningful improvements in irritability observed in a prespecified adolescent subgroup.67d ago

Similar companies

Genfit S.A.GNFT Allogene Therapeutics, Inc.ALLO BlossomHill Therapeutics, Inc.BLSM Oculis Holding AGOCS Prothena Corporation plcPRTA Altimmune, Inc.ALT Find similar companies →

Latest newsMore news →

MapLight Therapeutics reported financial results for the second quarter ended June 30, 2026, ending the quarter with $351.3 million in cash, cash equivalents and investments.67d ago MapLight Therapeutics reported Phase 2 IRIS results for ML-004 in autism spectrum disorder, with clinically meaningful improvements in irritability observed in a prespecified adolescent subgroup.67d ago MapLight Therapeutics announced a private placement financing (PIPE) to raise approximately $150 million in gross proceeds from institutional and accredited investors.68d ago